Abstract | Bone never forms without vascular interactions. This simple statement of fact does not adequately reflect the physiological and pharmacological implications of the relationship. The vasculature is the conduit for nutrient exchange between bone and the rest of the body. The vasculature provides the sustentacular niche for development of osteoblast progenitors and is the conduit for egress of bone marrow cell products arising, in turn, from the osteoblast-dependent haematopoietic niche. Importantly, the second most calcified structure in humans after the skeleton is the vasculature. Once considered a passive process of dead and dying cells, vascular calcification has emerged as an actively regulated form of tissue biomineralization. Skeletal morphogens and osteochondrogenic transcription factors are expressed by cells within the vessel wall, which regulates the deposition of vascular calcium. Osteotropic hormones, including parathyroid hormone, regulate both vascular and skeletal mineralization. Cellular, endocrine and metabolic signals that flow bidirectionally between the vasculature and bone are necessary for both bone health and vascular health. Dysmetabolic states including diabetes mellitus, uraemia and hyperlipidaemia perturb the bone-vascular axis, giving rise to devastating vascular and skeletal disease. A detailed understanding of bone-vascular interactions is necessary to address the unmet clinical needs of an increasingly aged and dysmetabolic population.
Introduction
Bone never forms without vascular interactions. 1, 2 Whilst anatomically apparent, the physiological and pharmaco logical implications of this dynamic relationship are under-appreciated. The vasculature is, of course, the conduit for nutrient exchange between the skeleton and the rest of the body; this vasculature is required to provide rapid access to the skeletal calcium 'bank' needed when physiological demands are urgent 3 -be it for deposits or withdrawals-but also for the delivery of metabolic substrate to the basic multicellular unit underlying the bone-forming functions of osteoblasts. 4 The vasculature also provides the niche for development of osteo progenitors. 5 Via its conduit functions, the vasculature enables egress of bone marrow cell products arising, in turn, from the osteoblast-dependent haematopoietic niche. 6 A comprehensive understanding of bonevascular interactions during development and disease is required to better address the burgeoning clinical needs of our aging, dysmetabolic population. 7 Remarkably, the inextricable interdependence of vascular physiology, skeletogenesis, bone remodelling and mineral metabolism has, in general, escaped widespread appreciation. Arteriosclerosis-the stiffening of conduit arteries from any cause, including medial calcification and fibrosis in addition to atherosclerosis-contributes to disorders that increase morbidity and mortality, such as musculoskeletal disease. The lower extremities bear the brunt of this disease burden, which is best manifested in the increased risks of hip fracture, 8 limb ischaemia 9, 10 and amputation. 9, 11, 12 In a preclinical model of critical limb ischaemia, Napoli et al. have begun to capitalize upon this physiology, coupling parathyroid hormone (PTH)-mediated bone anabolism with treatment with granulocyte colony stimulating factor as a strategy to mobilize endothelial progenitor cells and improve limb recovery. 13 In humans, several groups have demonstrated that marrow-derived progenitors with 'osteogenic signatures' portend and participate in arterial function, 14, 15 valve calcification 16 and fracture repair. 17 Anabolic crosstalk between osteoblasts and endothelial cells has been manipu lated as a successful strategy to enhance bone regeneration following injury. 18, 19 Thus, a bonevascular axis has emerged, in which the vasculature supports musculo skeletal functions, and bone-derived cell types and endocrine and/or para crine cues affect vascular health.
This Review provides an overview of the intricacies of the bone-vascular axis, emphasizing interactions dur ing disease rather than during development (two out standing reviews detail these interactions during skele tal morpho genesis impairs calciotropic hormone signals vital to the preservation of normal bone and vascular mineral homeostasis. [27] [28] [29] Also discussed are the mechanisms whereby cellular, biochemical and hormonal cues produced by the skeleton systemically affect vascular health and vessel conduit function. The Review ends by pointing to emerging therapeutic opportunities afforded by an improved understanding of the bone-vascular axis.
Vascular calcification and human health
Vascular calcification has afflicted human beings for at least 5 millennia. Ötzi, the Tyrolean Ice Mummy who succumbed to homicide ~5,300 years ago-500 years before Stonehenge was erected-had considerable deposits of arterial calcium in his abdominal aorta. 30 Only in the past few decades have the physiological consequences of arterial calcification become evident-a clinical appreciation afforded by the greater longevity enjoyed by modern humans. Coronary artery calcium scores identify individuals at the greatest risk of progressive cardiovascular disease among patients with otherwise intermediate risk. 31 Tibial artery calcium (TAC) scores outperform ankle-brachial indices in portending amputation risk in
Key points
■ Clinically important and actively regulated processes control tissue mineralization in the skeleton and the arterial vasculature ■ Bidirectional communication between the vasculature and bone-conveyed by cellular, endocrine and metabolic messengers-is critical to maintenance of bone health and vascular health ■ Dysmetabolic states, such as diabetes mellitus, uraemia and hyperlipidaemia, perturb the bone-vascular axis and give rise to vascular and skeletal disease ■ As understanding of the bone-vascular axis continues to improves, so too will our capacity to meet the clinical needs of patients with metabolic bone and cardiovascular disorders patients with peripheral arterial disease (PAD). 9 Furthermore, assessment of patients with type 2 diabetes mellitus (T2DM) with plain radiographs revealed that the presence of arterial medial calcification was a greater contributor to amputation risk than atherosclerotic calcification in this patient population. 12 The presence and extent of calcific aortic valve disease is the single best predictor of clini cal progression in patients with asymptomatic, mild or moderate, 32 or severe 33 calcific aortic stenosis. London and colleagues used plain pelvic and femoral radio graphs to phenotype vascular calcification in a setting of end-stage renal disease (ESRD) requiring renal replacement therapy; the researchers observed that arteri al calcification clearly portended mortality. 34 Although the calculated 5-year Kaplan-Meier survival rate was <50% for patients with ESRD affected by athero sclerotic calcification or medial calcification, the fortunate one-third of patients lacking clinically significant arterial calcification enjoyed ~90% survival during the same period. 34 After adjustment for age, time on dialysis, sex, ethnicity, presence of diabetes mellitus, non-dialysis chronic kidney disease (CKD) status, hypertension, tobacco use, existence of prior parathyroid surgery and BMI, patients with atherosclerotic calcification and medial calcification had fivefold and 16-fold increases, respectively, in the relative risk of mortality compared with those without vascular calcification. 12 In the past year, a study in which CT-based volumetric scoring of carotid artery calcification load was used, intracranial carotid calcification was linked to the extent of MRI-detected central nervous system (CNS) white matter lesions and extracranial carotid calcification was linked to overt CNS infarcts. 35 Clearly, arterial calcific vasculo pathy is a harbinger of cardiovascular disease.
How can arterial calcification convey such clinically significant risks? Of course, thromboembolic events and fixed reductions in vessel lumen size induce tissue ischaemia, and the calcified Stary type Vb plaque, 36, 37 characteristic of atherosclerotic calcification, is a culprit lesion in acute coronary syndromes. 37, 38 Aortic valve sclero sis distorts and stiffens valve leaflets, not only causing stenosis with attendant myocardial workload demand but also precluding the efficient valve leaflet coaptation that prevents regurgitant flow. 39, 40 Additionally, conduit vessel stiffening (which arises from either atherosclerotic or medial mineraliza tion) 41 impairs Windkessel physio logy, 42 which depends upon the rubbery elasticity of conduit vessels and is necessary for smooth distal tissue perfusion (Figure 1 ). 43 With each cardiac cycle, a portion of the kinetic energy elaborated during ventricular systole is stored as potential energy throughout the vascular tree; 42 this energy is released during diastole and helps maintain uniformity of flow in distal capillary beds during the cardiac cycle. 43 More over, with arterial stiffening, the attendant increase in pulse wave velocity interacts with an impedance mismatch along the vascular tree to elevate systolic blood pressure, increasing myocardial workload as well as endorgan barotrauma (Figure 1) . 43, 44 Thus, the presence, extent and histoanatomic type of arterial calcification carries ominous predictions with respect to cardio vascular and CNS disease, mortality and amputation risk. Figure 1 | Consequences of arterial stiffening and impaired Windkessel physiology. During systole, some kinetic energy is stored as potential energy in the elastic conduit arteries. This stored energy permits not only coronary perfusion but also smooth distal capillary perfusion during diastole (blue tracing). With arteriosclerotic stiffening (red tracing), less potential energy is stored during systole, giving rise to impaired, pulsatile and erratic flow during diastole (two-thirds of the cardiac cycle). 210 Systolic blood pressure is also increased. The topic has been reviewed elsewhere. 81 At this point, the differences denoted when using the terms arteriosclerosis and atherosclerosis should be highlighted. Arteriosclerosis refers to arterial mechanical stiffening from any cause, be it from concentric medial and adventitial fibrosis with medial calcification, elastino lysis and mural thickening, as occurs in T2DM; eccentric intimal-medial atherosclerotic plaques with calcification, fibrosis and cholesterol-laden lipoprotein deposition; or neointima formation and mural fibrosis, as occurs in chronic allograft vasculopathy in transplanted organs. Atherosclerosis specifically refers to the intimally oriented, eccentric, lumen-deforming processes initiating from subendothelial lipoprotein deposits. Cholesterol-laden foam cell formation, endothelial dysfunction, and matrix remodel ling events increase the risk of acute atherothrombosis with atherosclerosis. Although atherosclerosis decreases arterial compliance by causing arteriosclerosis, not all arteriosclerosis arises from at herosclerotic processes.
Vascular calcification: pathobiology
Vascular calcification was once considered only a pas sive process of dead and dying cells; however, data from a multitude of laboratories worldwide have clearly demon strated that vascular calcification is an actively regu lated form of extracellular matrix biomineralization. 21 Virchow's initial pathological description of athero sclerosis presciently identified the contributions of perturbed lipid metabolism, inflammation and osteo-fibrogenic differen tia tion to the biology of vascular calcium accrual. 45, 46 Of note, vascular os sification-presence of true ectopic bone replete with marrow elements-can be seen in up to 15% of calcified arterial lesions. 47 At the molecular level, however, the signature of active osteogenic processes is found in virtually all calcified arterial segments. 48 Seminal studies from the laboratories of Linda Demer and H. Clark Anderson first identified the osteogenic 'fingerprints' in calcifying athero sclerotic and medial lesions. 48 Alkaline phosphatase, tissue-nonspecific isozyme (TNAP)-a highly characteristic and important ectoenzyme required for bone m ineralization 49 -was localized to mineralizing arterial segments. 50, 51 More over, the powerful bone morphogen BMP-2 was shown to be expressed in calcifying athero sclerotic plaques of human vessels. 52 Oxylipids derived from oxidized LDL (oxLDL) were subsequently identified as potent inducers of endothelial BMP-2, 53, 54 TNF 55 and other macrophage-derived signals that drive mineraliza tion of calcifying vascular cells (CVCs) in vitro and in vivo (see below). 55 However, in athero sclerotic mice, inhibition of arterial BMP-2 signalling with matrix Gla protein (MGP) reduces vascular calcium and lesion size. 56 By histoanatomic and clinical criteria, at least five types of arterial calcification can be identified (Table 1) : atherosclerotic calcification, medial artery calcification, calcific aortic valve disease (also known as calcific aor tic stenosis), calcific uraemic arteriolopathy (also known as calciphylaxis) and the vascular calcification of ESRD (also known as CKD-MBD, chronic kidney disease mineral and bone disorder). The different types of ar terial calcification have been discussed in-depth in previous reviews. 22, 57 For the purposes of this Review, only athero sclerotic calcification, medial calcification and vascular calcification of CKD-MBD will be briefly discussed because of their immediate relevance to skeletal physiolog y and bone-vascular interactions.
Atherosclerotic calcification
Atherosclerotic calcification represents the prototypic lesion described by Virchow. 45, 46 In the lexicon of cardiov ascular pathology, this is the type Vb plaque, 58 characterized by an eccentric, lumen deforming, outward remodelling lesion possessing a fibrous cap, cholesterolladen macrophages and lipoprotein deposits, intensive focal inflammatory cell infiltration and localized elastinolysis ( Figure 2) . 37, 38 Juxtaposed mineraliz ing apoptotic bodies and mineralizing matrix vesicles are elaborated by neighbouring vascular smooth muscle cells (VSMCs) and CVCs undergoing chondroid metaplasia. 37, 38 Stippled fibrous cap calcification is also noted, and such lesions appear to be pre cursors to the ruptured plaques of acute coronary syndromes. 37, 38 In bone, biomineralization occurs via either endo chondral ossification or membranous ossification processes programmed by chondrocytes and osteoblasts. [59] [60] [61] Endochondral ossification is characterized by the mineraliza tion of a chondrocyte-derived skeletal template, following chondrocyte hypertrophy, apop tosis, vascular invasion and concomitant osteoprogenitor recruitment with subsequent osteoblastmediated bone formation.
Of note, Runx2 (also known as Cbfa1)-a master transcriptional regulator absolutely essential for both endochondral and membranous ossification processes 62 -is upregulated in the vessel walls of apoE -/-mice under going atherosclerotic calcification. 63 Elegant studies by the Giachelli laboratory have demonstrated the 'trans differentiation' of arterial VSMCs to cells of the chondrocyte and osteoblast lineage during vascular calcification ( Figure 3) . [64] [65] [66] Utilizing a transgenic mouse model in which cells originally derived from the VSMC lineage are forever 'tagged' , these researchers demonstrated that locally-derived VSMCs ended up as vascular chondro cytes and osteoblasts in the mineralizing segments. 65 VSMC trans differentiation in MGP -/-mice occurred in the absence of augmented MSX-2, Wnt or Sp7 (also known as Osx) signalling. 65 What then triggers osteochondrogenic transdifferentiation of VSMCs? Oxidative stress signal ling, oxy lipids and phosphate (see below) have important pathophysiological roles in this process ( Figure 3) . 67 Oxysterols (derived from oxLDL) and hydrogen peroxide upregulate Runx2 expression 68 and osteo chondrogenic transdifferen tiation of VSMCs. 69 Activation of TNAP in these VSMCs is critical to matrix mineralization responses elicited by oxLDL and hydrogen peroxide, and inhibitors of TNAP limit atherosclerotic calcification by VSMCs. 70 Intriguingly, hypercholesterolaemia and oxylipids derived from oxLDL also suppress bone formation 71, 72 and bone anabolic responses to PTH. 29, 73 Moreover, PTH responses were restored by administration of HDL mimetics. 29, 73 These data reveal a metabolic milieu that can simulta neously engender atherosclerosis and osteoporosis. Thus, inflammatory oxylipids and oxLDL accumulating at sub-intimal venues drive atherosclerotic intimal calcification by activating osteogenic BMP-2 and Runx2 transdifferentiation of VSMCs. 67, 74 Recruitment of CVCs 75 -mural multipotent mesenchymal cells related to microvascular pericytes 76 -provides an additional source of osteoprogenitors. 52 Arterial medial calcification Arterial medial calcification (sometimes called Mönckeberg's medial calcific sclerosis) is particularly common in arteriosclerosis associated with T2DM. [10] [11] [12] 77 Medial calcification is a concentric process that occurs in the tunica media and is associated with biomineralization initiating along mural elastin fibres ( Figure 2 ). 78, 79 Traditionally, medial calcification was thought to be clinically inconsequential. This idea was succinctly articulated in a pathology textbook published in 1984, in which medial calcification was referred to as a disorder "of relatively little clinical significance", which "accounts for roentgenographic densities in the vessels of the extremities of aged individuals, but it is to be remembered that the lesions do not produce narrowing or occlusion of the vascular lumen". 80 Yet, as subsequently highlighted, medial artery calcification impairs vessel mechanics and the Windkessel physiology necessary for smooth distal tissue perfusion 81 and is the best predictor of risk of lower extremity amputation in patients with T2DM. 12 Similar to the membranous ossification of craniofacial bone-in which osteoblast-mediated biomineralization occurs in a matrix based on type I collagen without a preceding cartilage te mplate 61 -medial artery calcification does not involve overt chondro genesis during disease initiation; 82 however, chondrogenesis is sometimes seen in advanced disease with true ectopic ossification. 83 Electron microscopy first identified vesicles positive for TNAP associated with fragmented elastin in human arteries with medial artery calcification. 50 Additional insights into the pathobiology of disease initiation and progression have been forthcoming from detailed study of preclinical disease models. 22 When fed high-fat diets characteristic of westernized societies, male Ldlr -/-mice develop obesity, T2DM and dyslipidaemia, 22 with progressively severe medial artery calcification and subsequent atherosclerotic calcification as plaques begin to accumulate. 82 At the earliest phases of disease, ar terial Msx2 and Msx1 (genes encoding osteoblast homeodomain transcription factors essential for membranous bone formation in the skull) 84 are upregulated in the aortas of these animals. 85 Immunohistochemistry and in situ hybridization demonstrated the expression of MSX-2 in aortic valve interstitial myofibroblasts, arterial adventitial myofibroblasts and a subset of cells within the tunica media. 25, 48, 85 Data from our laboratory and others have contributed to the characterization of adventitial myofibroblasts as pericyte-like CVCs with multi-lineage mesenchymal cell potential (Figure 3 ). 86 As in atherosclerotic calcification, inflammation is again key in medial artery calcification; 22 diabetes mellitus with or without dyslipidaemia upregulates adventitial TNF 87 production by monocytes and macrophages, 55 which in turn induces pro-calcific MSX-2 activity and paracrine Wnt signalling cascades that promote mural calcification and fibrosis (Figure 3 ). 82 Along with BMP-2, a powerful bone morphogen secreted by inflamed endo thelial cells, 88 MSX-regulated Wnt family members produced by myofibroblasts and endothelial cells support the osteogenic differentiation and collagenous matrix mineralization by mesenchymal progenitors, [89] [90] [91] be it in bone 92 or within the arterial wall. 25, 91 Thus, the paracrine polypeptide milieu Adventitial-to-medial biological signals drive concentric involvement of arterial vessels in diabetes-associated medial calcification-which is quite a distinct process from the eccentric athero sclerotic calcification processes organized by sub-intimal oxylipid deposits (Figure 2) . In diabetic arteriosclerosis, neo angiogenesis arising from the vasa vasorum in the inflamed ad ventitial-medial junction circumferentially upregulates mural BMP-Wnt signalling, and spawns additional adventitial myofibroblasts that can be allocated and/or programmed to produce osteogenic and fibrogenic pheno types (Figure 3) . 94, 95 Not surprisingly, surgical stripping of arterial adventitia reduces medial c alcification in preclinical disease models. 96 Of note, data from several laboratories have demonstrated that similar processes contribute to aortic valve calcification directed by valve interstitial cells. 97 Activation of MSX and Wnt signalling cascades is observed in calcifying human aortic valves, 98 and apoE -/-mice lacking the Wnt receptor LRP-5 are protected from valve calcium accrual. 99 The behaviour and molecular phenotype of the three calcifying vascular mesenchymal cell p opulations-CVCs, adventitial myofibroblasts and valve interstitial cells-closely resembles that of the pericyte, the proliferative microvascular smooth muscle cell that maintains capil lary integrity during neoangiogenesis. 100 Thus, as occurs in atherosclerotic calcification, medial calcification and valve calcium accrual are driven in great part by osteogenic cells derived from vascular residents (Figure 3) . 21 However, exciting new data have led to the identification of a circulating CD45 + , osteocalcin-positive osteoprogenitor (COP) cell that elaborates BMP family members and 'homes' to sites of vascular injury. 16 As initially formulated by EghbaliFatourechi et al. in their elegant studies of human bone growth and fracture repair, 17 circulating osteo progenitors may also participate in vascular mineralization processes in T2DM 101 as well as in true ectopic vascular ossification. 102 Therefore, strategies that inhibit vascular BMPWnt signalling or reduce COP cell populations may help alleviate the burden of arteriosclerotic disease in T2DM.
Vascular calcification in CKD-MBD
In 2005, the KGIDO (International Group on Kidney Dis ease: Improving Global Outcomes) codified the clinical entity CKD-MBD, the mineral and bone disorder of chronic kidney disease that encompasses the vas cular calcification of CKD. 103, 104 In CKD-MBD, the clini cal link between bone disease and vascular disease arising from primary perturbations in calcium phosphate homeo stasis is now formally recognized. Diabetes mellitus and hypertension-two diseases that independently promote arterio sclerotic calcification-are responsible for approximately 60% of patients with ESRD requiring renal replacement therapy; 105 however, the vast majority of patients with CKD from any cause experience increased cardiovascular-related mortality and calcific vasculo pathy. 34, 106 Whilst antecedent diabetes mellitus, hyper tension, dyslipidaemia and the metabolic syndrome continue to contribute to arteriosclerosis, 107 hyperphosphataemia, reduced Klotho expression and impaired softtissue calcification defences are key pathophysiological components of CKD-MBD. 108, 109 Indeed, even in the setting of normal renal function, serum phosphate levels track severity and extent of coronary artery calcium. 110, 111 Hyperphosphataemia and hypercalcaemia increase the production of VMSC matrix vesicles-~100 nm diameter phosphatidylserine-rich and annexin-rich, bilaminate spheroids resembling the mineral izing vesicles of chondrocytes. 112 Reynolds et al. demonstrated that VSMCs produce these matrix vesicles as one mechanism to clear extra cellu lar matrix calciprotein complexes (Figure 3) . 112, 113 How ever, these same matrix vesicles can serve to nucleate and propagate extracellular matrix mineraliz ation in the absence of cell-mediated pinocytotic uptake. 113 Matrix vesicle uptake by VSMCs requires serum fetuin, 113 a hepatocyte-derived calcium-binding protein that maintains calcium solubility in the supersaturated serum and interstitial fluid compartments. 114 Dialysis reduces serum fetuin levels, as does inflammation. 115 In addition to increasing matrix vesicle release, phosphate also increases BMP-2 expression by VSMCs and upregulates VSMC Runx2 and MSX-2 via PiT-1 signalling.
65,116 BMP-2, in turn, further enhances phosphate uptake and osteogenic programming of VSMCs in a feedforward vicious cycle. 117 Thus, similar to oxLDL and hydrogen peroxide, elevated serum phosphate levels can reprogram the VMSC pheno type to support osteogenic mineral deposition. 66 Furthermore, sustained hyperphosphataemia simultaneously induces VSMC apoptosis, removing the first-line cell-mediated mechanism for clearing vascular calciprotein complexes. 118 The ensuing vascular mineral deposition is an exuberant medial calcification that is almost always superimposed on ante cedent athero sclerotic and medial calcification arising from diabetes mellitus, dyslipidaemia and other causes. Finally, with the massive increase in mural extracellular matrix calcium, the second-line defences for handling vascular extracellular matrix calcium, the cells of the monocyte and macrophage lineage, are recruited. 119 Vascular calcium phosphate deposition elicits innate immune responses by monocytes or macrophages, 120 increasing production of TNF 121 and downstream activation of osteo genic BMP, MSX, Wnt and Runx2 signalling 116, 121 -yet another feedforward vicious cycle in vascular minerali zation. Thus, patients with CKD suffer the 'perfect storm' of vascular calcification.
Perhaps not surprisingly, therefore, statin-based strat egies focused upon LDL cholesterol reduction have generally failed to reduce cardiovascular-related morbidity and mortality in ESRD. 122 This past year, a combined approach using a statin and the cholesterolabsorption inhibitor ezetimibe reduced major atherosclerotic dis ease end points by 20%, including the risk of non-haemorrhagic stroke, but failed to significantly reduce the risk of myo cardial infarction or associated death. 123 Strategies that emphasize phosphate binders as a primary approach to control hyperphosphataemia have met with early success, as long as the binding was not calcium-based. [124] [125] [126] As highlighted by Raggi et al., the use of calcium-based phosphate binders substantially contributes to vascular calcium load in ESRD. 127 This effect may be directly related to the impaired capacity of the uraemic skeleton to rapidly handle serum calcium transients. Indeed, London et al. demonstrated that patients with the most extensive vascular calcification exhibited the lowest levels of bone formation as assessed by histomorphometric evaluation, which was reflected in inappro priately normal or low PTH values. 128 As com pared to sevelamer-the first phosphate binder that does not contain calcium or aluminium-calcium-based phos phate binders suppress PTH, reduce bone mass and increase vascular calcium load in ESRD. 127 Because of the biphasic relationships between PTH, vitamin D and vascular health in ESRD, a rigorous focus upon the role and endocrine physiology of calciotropic hormones and calcium phosphate homeostasis should provide new hope to patients with CKD. 129 
Regulation of vascular calcification
Vascular calcification is clearly an actively regulated form of extracellular calcified matrix metabolism; however, remarkably few studies have been undertaken to investigate the regulation of vascular calcification by calciotropic hormones. 130 The prototypic calciotropic hormones are PTH, vitamin D and its metabolites, PTH-related protein (PTHrP), calcitonin and estrogens including estradiol. Estrogen signalling via non-genotropic signalling mechanisms acutely activates endothelial nitric oxide synthase in caveolae-an acute vasodilatory response that is theoretically protective. 131 Estrogen exposure in women was shown to reduce the incidence of arterial calcification as revealed from mammo graphy. 132 In the Rancho Bernardo Study, estrogen use in post menopausal women was associated with reduced coronary artery calcification; 133 however, estrogen replacement therapy worsened cardio vascular end points in older women in the Women's Health Initiative, 134 and estrogens including low-dose oral contraceptives are associated with PAD. 135 No published studies have examined the actions of calcitonin on arterio sclerosis, but the calcitonin gene-related peptide 1, encoded by the calcitonin gene, is a vasodilator. 136 Vitamin D insufficiency is associated with PAD 137 as well as other cardiovascular diseases, including congestive heart failure. 138 Additionally, vitamin D inhibits foam cell formation and macrophage activation in patients with T2DM. 139 However, vitamin D replacement has not been shown to improve any primary cardiac end point-although the largest studies have not used uniform preparations of vitamin D. 140 In ESRD, a biphasic, U-shaped, bimodal response to calcitriol levels has clearly emerged with respect to vascular disease (Figure 4a) . 141 Whilst vitamin D insufficiency and reduced levels of 1,25-dihydroxyvitamin D in ESRD engender more-severe secondary hyperparathyroidism, excessive 1,25-dihydroxyvitamin D dosing can induce low-turnover bone disease and hypoparathyroidism, and increase vascular calcium deposition. As London et al. first established, patients with ESRD who had the most extensive and severe arterial calcification exhibited the lowest bone formation rates and PTH levels. 128 Vitamin D intoxication induces widespread vascular calcification and nephrocalcinosis, and rodents with vitamin D intoxication are commonly used as models of vascular calcification thus highlighting the bimodal relation ship in ESRD. 142, 143 The calcium-sensing receptor is expressed in VSMCs as well as in parathyroid glands, 144 and signalling with this agonist to control secon dary hyperparathyroidism in uraemic rat models results in reduced vascular calcium accrual. 145 Of note, in cultured VSMCs, calcitriol induces calcification in part by suppressing PTHrP production and inducing TNAP. 146 Via para crine actions, PTHrP relaxes smooth muscle cells, inhibits fibroproliferative responses, prevents TNAP induction and inhibits calcium deposition by signalling via the PTH/PTHrP receptor (PTH1R). 146 Indeed, adenoviral delivery of the obligatory paracrine form of PTHrP inhibits neo intima formation in a porcine model of stent-induced coronary restenosis. 147, 148 The role of PTHrP-PTH1R signals in the VSMC in the setting of cardiovascular arterio sclerosis has not been exhaustively studied to date, in part because Pth1r -/-mice die Figure 4 | The biphasic relationship between cardiovascular disease and calciotropic hormones. As in all key endocrine systems, a 'sweet spot' exists that represents the optimal set point for calciotropic hormone levels and vascular health. a | Both calcitriol excess and deficiency have been associated with cardiovascular disease, 141, 213 and also observed in children with chronic kidney disease. 214 b | Similar cardiovascular problems arise with either excesses 197 or insufficiencies 127, 128 in PTH. Abbreviations: AT-II, angiotensin II; IMT, intima-media thickness; PTH, parathyroid hormone; PTHrP, parathyroid hormone-related protein; VSMC, vascular smooth muscle cell.
in utero owing to massive cardiomyocyte apoptosis. 149 Nevertheless, the postnatal vasculopathy arising from vitamin D intoxication may involve lesioning of protective paracrine PTHrP-PTH1R signals in VSMCs in ad dition to hyperphosphataemia and hypercalcaemia. 145, 146 This past decade, our group examined the impact of PTH1R signalling on arteriosclerotic calcification in the Ldlr -/-mouse model. [23] [24] [25] Bone anabolic responses that increased skeletal calcium accrual were accompanied by reductions in aortic calcium accrual. 23, 24 Addi tionally, arterial expression of osteogenic genes was downregulated whilst skeletal expression of these same genes was increased. 24, 25 PTH1R is highly expressed in VSMCs, and is very susceptible to homologous desensiti zation upon tonic exposure to PTH or PTHrP. 150 Of note, sustained pharmacologic vascular exposure to either PTHrP or PTH-mi micking the setting of hyper parathyroidism -induces arterial tachyphylaxis to acute PTH or PTHrP agonist administration in vitro. 150 In order to address the potential VSMC-autonomous role of PTH1R signalling in arteriosclerotic vascular responses, transgenic mice were generated and evaluated. 23 In these animals, a ligand-independent, constitu tively active form of PTH1R, PTH1R(H223R), 151 is expressed in VSMCs under the control of a VSMC-specific promoter, the SM22 promoter. 23 As compared with nontransgenic male siblings, male SM22-PTH1R(H223R);Ldlr -/-mice exhibited reduced aortic calcification, aortic fibrosis and aortic oxidative stress. 23 Arteriosclerotic Wnt-β-catenin signalling and type I collagen gene expression were concomitantly reduced. 23 Aortic wall thickness was also decreased, and ex vivo vessel mechanical compliance (distensibility) was increased. Importantly, Sebastian et al. independently demonstrated that pulsatile administration of PTH reduces arterial mineralization in a rat model of uraemia, although fibrosis and vessel mechanics were not evaluated. 26 Our in vivo data with the SM22-PTH1R(H223R) transgene demonstrate that sustained activation of PTH1R in VSMCs actually reduces vascular oxidative stress and pro-calcific and pro-fibrotic signals that drive arteriosclero tic disease. 23 Of note, dysmetabolic states associated with macrovascular disease, such as diabetes mellitus, dyslipida emia and uraemia, induce tissue resistance to PTH1R activation. 27, 29, 152 These findings converge to prompt a major reconsideration in our thinking as concerns the pathobiology of arteriosclerosis in T2DM and other dysmetabolic states, including primary and s econdary hyperparathyroidism.
How do these findings begin to change our view? The negative impact of dysmetabolic states (dyslipidaemia, diabetes mellitus, uraemia) on PTH1R signalling can be seen as inducing insufficiency in endocrine or paracrine PTHrP actions that help preserve vascular health. The increase in carotid intima-media thickness associated with primary hyperparathyroidism 153 might be viewed, in part, as being the consequence of homologous vascular desensitization, 150, 154 which occurs in response to tonically elevated PTH levels and impaired capacity of paracrine production of PTHrP in VSMCs to restrain proliferative 155 and calcific 146 arteriosclerotic responses (Figure 4b ). However, via its bone anabolic actions, PTH signalling upregulates circulating intact osteopontin 24 -an inhibitor of vascular mineralization-and supports the haemato poietic niche, including cellular elements such as endo thelial progenitor cells that programme vascular healing responses. Furthermore, PTH upregulates the expression of MGP, 156, 157 an important negative regulator of matrix mineralization and BMP-2 and BMP-4 signalling in the vasculature. 56 Whether MGP participates in PTH inhibition of vascular myofibroblast BMP-2 signalling 25 remains to be evaluated. The relative contributions of direct versus indirect actions of PTH1R on vascular health are under going additional scrutiny.
Arteriosclerosis and skeletal health
Atherosclerosis, calcification, mural hypertrophy and fibrosis, and elastin matrix senescence cause arteriosclerosis, the age-associated vascular stiffening that impairs the Windkessel physiology necessary for smooth distal tissue perfusion. With aging, vascular remodelling processes can increase wall thickness and regionally reduce conduit artery lumen patency, thus worsening arterial compliance and its clinical impact. 43 In the musculo skeletal system, the lower extremities experience the brunt of arteriosclero tic disease. Claudication and amputation are the most salient manifestations that reduce mobility and increase morbidity, but hip fracture is also increased with PAD. 8 Multiple studies have now established that the presence and extent of arteriosclerotic calcification conveys lower extremity amputation risk. Medial arterial calcification in T2DM conveys a threefold increased risk of amputation. 12 By use of CT scanning and the Agatston method to quantify TAC, Guzman et al. established that TAC scoring outperforms ankle-brachial indices in predicting lower extremity amputation risk. 9 Applying the conventional ankle-brachial indices method to characterize PAD, Collins et al. showed that PAD increased the rate of femoral neck bone loss and increased the risk of hip fracture in men. 8 They concluded that "further research should examine the biological mechanisms underlying the association between reduced limb blood flow and fractures". 8 The increasing prevalence of T2DM and associ ated PAD will contribute to the future arteriosclerotic disease burden in our society.
Atherosclerotic deposits can and do affect bone marrow arteries. However, the physiological responses of bone to arteriosclerosis are multifactorial. In 1985, Brenneise and Squier examined the relationship between atherosclerotic disease and blood flow in rhesus monkeys maintained on high-fat atherogenic diets. 158 These diets induced the formation of extensive calcified atherosclerotic carotid plaques, as well as atherosclerotic changes in arteries perfusing skeletal muscle. However, atherogenic diets failed to induce substantial atherosclerotic changes in the principal nutrient arteries of maxillary and mandibular bone-and did not alter osseous lumen area, intraosseous vessel wall thickness, vessel lumen area or lumen tissue area. 158 Nevertheless, atherosclerosis reduced osseous blood flow by 80% in the anterior mandible, posterior mandible and maxilla. 158 How can this situation occur? These seminal findings indicated that macrovascular Windkessel function and endothelial function, which are necessary for regulating bone tissue perfusion, are severely impaired with atherosclerosis and arteriosclerosis. 81 Our group has described and characterized a novel mouse model of arterio sclerotic vascular stiffening-the osteopontin (OPN)-null mouse on the LDLR-deficient background. Even in the absence of atherogenic diets, male Opn -/-;Ldlr -/-mice exhibit aortic adventitial fibrosis and vascular stiffening. Use of fluorescence microsphere perfusion assays demonstrated significantly reduced lower extremity bone (femur) blood flow in arteriosclerotic Opn -/-;Ldlr -/-animals. 159 By contrast, blood flow to the kidneys was not significantly altered as assessed with this assay. Thus, arteriosclerosis and atherosclerosis impair skeletal blood flow. 158, 159 Of note, in healthy young long bone, diaphyseal blood flow is primarily centrifugal, with flow originating from the marrow compartment (supplied via the nutrient artery) to the trabeculae and bone cortex ( Figure 5 ). 160 How ever, with aging, flow becomes increasingly cen tripetal, with the greatest extent of diaphyseal cortex being perfused by periosteal arteries. 161 This age-dependent change in the 'vector' of blood flow may become more exaggerated owing to the enhanced sensitivity of the nutrient artery to vasoconstrictors as compared to vasodilators. 162 With aging, the vasodilator response in bone nutrient arteries becomes progressively reduced. 163 Blood flow is a critical determinant of the bone formation rate at the basic multicellular unit (BMU) within the adult skeleton. 4 The interactions between age-dependent changes in this cortical bone flow vector and arterio sclerotic conduit vessel stiffening have not been systematically examined. As osteoblast-mediated bone formation is directly related to perfusion, 4 these age-dependent changes are predicted to contribute to reduced skeletal anabolism in the absence of intervention.
Certainly, perfusion-dependent and diffusiondependent nutrient supplies must be rate-limiting contributors to the impairment of bone physiology with arterio sclerotic disease. Indeed, Prisby et al. highlighted that it is the proxi mity of the bone-forming BMU to the micro vasculature-not the mass of the skeletal m icrovasculature-that is critical in maintaining bone anabolism. 164 Vascular endothelial growth factor (VEGF), a prototypic angiogenic factor produced by osteoblasts, was shown to be critically important in this process; inhibition of VEGF prevented both microvascular alignment with the BMU and bone anabolic responses to PTH. 164 Moreover, the sub-intimal vascular accumulation of oxLDL in bone impairs anabolic responses to PTH. 27 However, it has become increasingly evident that the vasculature itself provides paracrine and juxtacrine cues that regulate osteoblast functions. 165 Ephrin-B2, BMP-2, RANKL and nitric oxide are but a few of the potent osteotropic signals expressed by endothelial cells. [165] [166] [167] [168] [169] [170] [171] Furthermore, the vasculature also provides the sustentacular niche for osteoblast progenitors, 172 and is the conduit for egress of bone-marrow-derived formed elements from the o steoblast-regulated haematopoietic niche. 173 Napoli et al. demonstrated the capacity of endocrine pharmacotherapy targeting skeletal osteoblasts and bone marrow to enhance ischaemic limb recovery in mice. 13 Thus, multiple bone-vascular interactions may contribute to impaired skeletal anabolism with arteriosclerosis. The important preclinical 'proof of principle' supplied by Napoli et al. 13 provides compelling pharmaco logic and physiological evidence for an emerging bone-vascular axis that regulates cardio vascular and skeletal health.
Vascular health and the bone-vascular axis
In the preceding sections the impact of vascular disease on skeletal function has been emphasized. However, in the past decade it has became clear that bone is in fact an endocrine organ, 174 capable of producing phosphaturic hormones such as DMP-1 and FGF-23, which are relevant to the pathobiology of vascular disease. 175 FGF-23 is an osteocyte-derived hormone that enhances phosphate excretion by the kidney via downregulation of proximal tubule sodium phosphate symporters. 176 Hyperphosphataemia and vascular calcification were observed in Fgf23 -/-mice-mitigated by simultaneous reductions in the enzyme CYP27B1. 177 Of note, FGF-23 directly suppresses CYP27B1. 178 Thus, the vascular toxicity arising from deficiency in this bone-derived hormone is due to endogenous calcitriol intoxication with hyperphosphataemia. 179 With declining renal function, post-prandial elevations in FGF-23 are amongst the earliest changes observed, 180 and probably serve as a bone-derived defence mechanism to limit the toxicities of hyper phosphataemia in conjunction with PTH. 175 With progressive uraemia, end-organ responses to FGF-23 are diminished owing to reduced Klotho co-factor expression by the kidney and parathyroid glands.
181-185
Younger centrifugal ow ascending and descending medullary arteries; this flow helps maintain a fairly high intramedullary pressure that drives centrifugal flow through cortical bone (~5 ml/min/g). 160 b | With aging 161 and arteriosclerosis, 158, 159 perfusion is altered, with blood supply to the aging cortex increasingly provided from periosteal conduit vessels. 161 Age-related and exercise-related changes in vasodilatation responses of nutrient arteries can also affect the extent of centrifugal versus centripetal cortical blood flow, 163, 215 as the nutrient arteries are more responsive to vasoconstrictors. 162 
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Of note, both FGF-23-Klotho 185, 186 and DMP-1 187 signal ling have been demonstrated to exert direct beneficial vascular actions. The kidney, therefore, emerges as a particularly important intermediary in the bone-vascular axis via hormonally regulated phosphate excretion and Klotho production ( Figure 6 ). Osteopontin, a very potent inhibitor of matrix mineralization in its phosphorylated form, 188 is secreted into the circulation by skeletal osteoblasts and its levels increase in response to bone anabolic stimuli such as PTH. 24 As osteoblast-derived osteopontin is highly phosphorylated 189 and stable to proteolysis, 190 this circulating pool of osteopontin may also serve as an important defence against vascular mineral accrual, as first posited by Jono et al. 188 Studies by Lee et al. have highlighted the important role of bone-derived osteocalcin as a Gla-dependent hormone controlling β-cell longevity. 191 With respect to arterio sclerosis, the capacity of osteocalcin to support adipo nectin production by adipocytes may be of particular importance. 191 Adiponectin suppresses the inflammatory responses elicited by TNF 192, 193 -an important stimulus for vascular calcification, as highlighted above. 82 Moreover, adiponectin-deficient mice develop arterial calcification that is mitigated by adenoviral-mediated vascular restoration. 194 Idelevich et al. have provided new evidence that osteocalcin may also directly enhance osteo chondrogenic mineralization of VSMCs; 143 this finding has yet to be confirmed in atherosclerotic disease models. Nevertheless, given that bone-marrow-derived cell types can either promote or limit vascular calcium accrual, two arms of the bone-vascular axis clearly emerge: one being cellmediated, via the para crine actions of osteoblasts on the haemato poietic niche and cell egress; and the other being humoral, via endocrine signals that derive from osteoblasts or osteocytes and regulate renal phosphate excretion, PTH production and vascular proximity to the BMU ( Figure 6 ).
In conclusion, with respect to diseases of the bonevascular axis, three relationships can now be envisioned Figure 6 | Clinical promises and pitfalls of the emerging bone-vascular axis. A bidirectional endocrine relationship exists between bone and the vasculature that mutually benefits bone and vascular health. The kidney is an important intermediary in this process, via regulation of phosphate excretion 182 and expression of Klotho. 109, 200 Importantly, PTH1R signalling maintains bone formation; sustains haematopoietic niche function 216 and endothelial progenitor cell mass; 13 promotes intact osteoblast osteopontin 24 and osteocyte FGF-23 198, 200 secretion; supports renal Klotho production; 200 and suppresses aortic osteofibrogenic Wnt/β-catenin signalling 23, 146 and vascular calcium accrual. 23, 26 PTH1R signalling also reduces aortic 23 and skeletal 217 oxidative stress, and maintains the proximity of the microvasculature to the BMU during bone formation. 164 Declining renal function and tissue resistance to PTH1R signalling are key features in the perturbation of the bone-vascular axis in the setting of disease. Age-related changes in marrow composition and the vector of bone perfusion ( Figure 5 ) may also functionally perturb the bone-vascular axis. Abbreviations: BMU, basic multicellular unit; PlGF, placental growth factor; PTH1R, PTH/PTHrP receptor; RANKL, receptor activator of nuclear factor κB ligand; VEGF, vascular endothelial growth factor. See text for details. (Figure 7) . Certainly, the metabolic milieu and genetics can independently cause arteriosclerotic and bone disease. Additionally, primary changes in arterio sclerotic vessel functions arising from the metabolic milieu and gen etics can cause bone disease via alterations in perfusion. How ever, new understanding of the bone-vascular axis indicates that primary disease changes in bone and bone marrow function arising from the metab olic milieu and genetics may, in turn, cause vascular disease. Under this last and novel view, a healthy skeleton and marrow helps preserve vascular health and function. The relative contributions of bone-derived cellular versus endocrine signals to changes in vascular physiology could be particularly important with respect to uraemia, aging and diabetes mellitus. 195 Indeed, Faul et al. have shown in the past year that FGF-23-which is secreted by osteo blasts and osteocytes in response to the phosphate retention that characterizes CKD-ultimately promotes left ventricular hypertrophy. 196 A better understanding of how bonederived endocrine cues and marrow-derived cell types interact to regulated vascular health is clearly necessary.
Conclusions
Preclinical and clinical studies performed over the past two decades have converged to highlight the presence and critical role of a bone-vascular regulatory axis in human health. Not unlike the famous legend of the three blind men describing the elephant, the perspectives of experts in endocrinology, cardiology, developmental biology, orthopaedics, biochemistry, genetics, pathology, engineering and haematology often emphasize different features of the bone-vascular axis. Fortunately, the assembly of these multiple viewpoints is providing an increasingly sharper image.
Calciotropic hormones have direct and indirect vasculo tropic actions deserving consideration; both excesses 197 and insufficiencies 128 in calciotropic hormones such as PTH engender vascular disease. The inabi lity to tightly regulate calcium phosphate homeo stasis results in vascular toxicity. Cellular and endocrine signals arising from bone and marrow have an impact on vascular physiology and function, and are maintained in part by PTH-dependent signals. 13, 182, 198 Age-dependent and disease-dependent changes in vascular physiology affect bone health and fracture risk. Inflammation, oxidative stress and oxylipid signals reciprocally regulate bone and vascular mineralization, and impair PTH1R signalling important to bone and vascular health. 29, 67, 199 The kidney is an important intermediary in the bone-vascular axis via hormonally regulated phosphate expression and Klotho expression. 182, 200 Declining renal function and tissue resistance to PTH1R signalling represent key features in the disease-associated perturbation of the bone-vascular axis ( Figure 6 ). Endocrine regulation of the bone-vascular axis is feasible; for example, strategies that modulate PTH1R signalling, end-organ responsiveness and calcium phosphate homeostasis offer opportunities to improve bone health and preserve vascular health in patients with diabetes mellitus, dyslipidaemia and uraemia associated with PAD. 13, 23, 29, 127, 201, 202 On a cautionary note, however, our understanding of the relationships between bone and vascular mineral homeostasis is rudimentary. As clinicians, we are coming to appreciate the reciprocal relationships between bone health and atherosclerosis as detected by vascular calcification; [203] [204] [205] [206] however, the endocrine regulation of this relationship might change with age. For example, aminobisphosphonate therapy for osteoporosis decreases the risk of aortic valve and thoracic aorta calcification in women aged >75 years but increases risk in women under age 55 years. 207 Furthermore, although helpful to bone in some contexts, oral calcium supplementation in patients with renal insufficiency 127 and advanced age 208, 209 may have a negative effect on cardiovascular health. As our understanding of the bone-vascular axis continues to improve, so too will our capacity to meet the clinical needs of patients with musculoskeletal and vascular diseases. Metabolic milieu, genetics Figure 7 | Relationships between the metabolic milieu, genetics, arteriosclerosis and musculoskeletal disease. a | Oxylipids simultaneously drive arteriosclerotic calcification, suppress bone formation and increase osteoclastogenesis; parallel progression of arteriosclerosis and musculoskeletal disease takes place. b | However, via vessel stiffening and reductions in endothelium-dependent control of bone perfusion, arteriosclerosis can negatively affect bone anabolic responses necessary for skeletal homeostasis and fracture repair. c | Finally, osteoblasts, osteocytes and bone marrow produce cellular elements and hormonal cues that prevent arteriosclerotic remodelling and preserve vascular health; therefore, primary disease of bone may give rise to, or at least exacerbate, arteriosclerotic disease. Factors that affect the metabolic milieu include aging, diabetes mellitus, dyslipidaemia, uraemia and inflammation.
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